https://www.pharmaradar360.com/article/la-aemps-informa-sobre-el-nuevo-sistema-de-evaluacion-de-tecnologias-sanitarias-1b67643d2579238ePharma Surgeen2026-07-17T10:59:32.000ZLa AEMPS informa sobre el nuevo Sistema de Evaluación de Tecnologías Sanitarias tras la aprobación del Real Decreto 415/2026https://www.pharmaradar360.com/article/rani-links-with-pegbio-to-grow-oral-obesity-pipeline-871aae4309ac2789Pharma Surgeen2026-07-17T10:41:11.000ZRani links with PegBio to grow oral obesity pipelinehttps://www.pharmaradar360.com/article/2-reasons-to-avoid-bmrn-and-1-stock-to-buy-instead-6daa4d1c5356c13aPharma Surgeen2026-07-17T10:37:50.000Z2 Reasons to Avoid BMRN and 1 Stock to Buy Insteadhttps://www.pharmaradar360.com/article/cspc-pharmaceutical-group-limited-announces-new-drug-application-for-trastuzumab-1b1895da709f0f6cPharma Surgeen2026-07-17T10:35:45.000ZCSPC Pharmaceutical Group Limited Announces New Drug Application for Trastuzumab Envedotin Injection Accepted by Nmpahttps://www.pharmaradar360.com/article/la-aemps-informa-del-robo-y-distribucion-ilegal-de-dos-lotes-de-sensores-dexcom-b6ac66382549252aPharma Surgeen2026-07-17T10:25:04.000ZLa AEMPS informa del robo y distribución ilegal de dos lotes de sensores Dexcom G7https://www.pharmaradar360.com/article/sanofi-sues-pfizer-and-moderna-for-patent-infringements-related-to-covid-vaccine-6505ae0e0eba5dc1Pharma Surgeen2026-07-17T10:12:37.000ZSanofi sues Pfizer and Moderna for patent infringements related to COVID vaccineshttps://www.pharmaradar360.com/article/guidance-ai-airlock-sandbox-phase-2-programme-report-73318c57a9ccf366Pharma Surgeen2026-07-17T10:11:27.000ZGuidance: AI Airlock Sandbox Phase 2 Programme Reporthttps://www.pharmaradar360.com/article/blossomhill-therapeutics-clinical-stage-oncology-biotech-files-for-nasdaq-global-06ea9eeed5096fc2Pharma Surgeen2026-07-17T10:08:00.000ZBlossomHill Therapeutics, Clinical-Stage Oncology Biotech, Files for Nasdaq Global Select Market IPOhttps://www.pharmaradar360.com/article/ph-eur-revises-general-chapter-on-alternative-microbiological-methods-49a12c52a3eedef2Pharma Surgeen2026-07-17T10:00:04.000ZPh. Eur. revises general chapter on alternative microbiological methodshttps://www.pharmaradar360.com/article/gsk-axes-key-cough-drug-candidate-after-phase-3-data-end-blockbuster-hopes-1dd70709621a8020Pharma Surgeen2026-07-17T09:46:34.000ZGSK axes key cough drug candidate after phase 3 data end blockbuster hopeshttps://www.pharmaradar360.com/article/cspc-pharmaceutical-says-nmpa-accepts-new-drug-application-for-trastuzumab-enved-b6ee04a40ea01175Pharma Surgeen2026-07-17T09:23:34.000ZCSPC Pharmaceutical Says NMPA Accepts New Drug Application For Trastuzumab Envedotin Injectionhttps://www.pharmaradar360.com/article/gsk-provides-an-update-on-calm-1-and-calm-2-phase-iii-trials-for-camlipixant-in-d872850514eca694Pharma Surgeen2026-07-17T09:00:00.000ZGSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)https://www.pharmaradar360.com/article/dimerix-snaps-up-mission-s-stalled-phase-2-ready-kidney-disease-candidate-in-292-ebadbf851225c36dPharma Surgeen2026-07-17T09:00:00.000ZDimerix snaps up Mission’s stalled, phase 2-ready kidney disease candidate in $292M dealhttps://www.pharmaradar360.com/article/veradermics-touts-oral-hair-loss-data-as-shares-jump-d63dcc8a8bee8213Pharma Surgeen2026-07-17T08:59:42.000ZVeradermics touts oral hair-loss data as shares jumphttps://www.pharmaradar360.com/article/cspc-pharmaceutical-group-s-stock-price-plummets-by-6-28-dipping-to-8-06-hkd-in-416ca95ed8ff0ad1Pharma Surgeen2026-07-17T08:41:30.000ZCSPC Pharmaceutical Group's Stock Price Plummets by 6.28%, Dipping to 8.06 HKD in Recent Tradinghttps://www.pharmaradar360.com/article/the-israeli-biotech-trying-to-make-damaged-nerves-grow-again-e37e82c32c9afa45Pharma Surgeen2026-07-17T08:40:00.000ZThe Israeli biotech trying to make damaged nerves grow againhttps://www.pharmaradar360.com/article/aman-nna-republic-of-korea-donates-korean-essential-medicines-to-strengthen-heal-f958e75112a19d58Pharma Surgeen2026-07-17T08:38:42.000ZAMAN - NNA - Republic of Korea donates Korean essential medicines to strengthen health cooperation with Lebanonhttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-nyse-teva-given-consensus-rating-of-moderate-40b2074aeebf67a5Pharma Surgeen2026-07-17T08:30:58.000ZTeva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Consensus Rating of "Moderate Buy" by Brokerageshttps://www.pharmaradar360.com/article/implementing-reporter-assay-based-mat-for-rapid-pyrogen-detection-bbb10d5d48332f87Pharma Surgeen2026-07-17T08:24:46.000ZImplementing reporter assay-based MAT for rapid pyrogen detectionhttps://www.pharmaradar360.com/article/alnylam-pharmaceuticals-nasdaq-alny-a-value-stock-priced-below-biotech-peers-wit-787a03631e9b3e6cPharma Surgeen2026-07-17T08:10:32.000ZAlnylam Pharmaceuticals (NASDAQ:ALNY): A Value Stock Priced Below Biotech Peers with Strong Growthhttps://www.pharmaradar360.com/article/biotech-growth-says-eli-lilly-s-2-8bn-swoop-on-ataibeckley-underlines-the-value-e3431c8719546379Pharma Surgeen2026-07-17T07:57:15.000ZBiotech Growth says Eli Lilly's $2.8bn swoop on AtaiBeckley underlines the value of smaller drug developershttps://www.pharmaradar360.com/article/qlife-targets-agreement-after-the-summer-098093059108f953Pharma Surgeen2026-07-17T07:45:50.000ZQlife targets agreement after the summerhttps://www.pharmaradar360.com/article/la-aemps-informa-del-riesgo-de-caidas-en-determinadas-gruas-winn-motion-34566e2764379ec1Pharma Surgeen2026-07-17T07:29:59.000ZLa AEMPS informa del riesgo de caídas en determinadas grúas Winn’Motionhttps://www.pharmaradar360.com/article/paradigm-biopharmaceuticals-asx-par-returns-to-the-spotlight-ahead-of-key-phase-f889d85265edb8b4Pharma Surgeen2026-07-17T07:17:00.000ZParadigm Biopharmaceuticals (ASX: PAR) Returns to the Spotlight Ahead of Key Phase 3 Trial Milestonehttps://www.pharmaradar360.com/article/topiramate-market-to-reach-usd-39-6-million-by-2036-supported-by-generic-antiepi-bd63fa93f2c9986aPharma Surgeen2026-07-17T07:03:23.000ZTopiramate Market to Reach USD 39.6 Million by 2036, Supported by Generic Antiepileptic Drug Production and Regulatory Compliance | Future Market Insightshttps://www.pharmaradar360.com/article/new-autologous-t-cell-therapy-offers-hope-for-children-with-brain-tumors-52e0d33b2719579dPharma Surgeen2026-07-17T07:03:11.000ZNew autologous T cell therapy offers hope for children with brain tumorshttps://www.pharmaradar360.com/article/dimerix-expands-pipeline-with-acquisition-of-phase-2-ready-asset-for-acute-kidne-ada51482882813efPharma Surgeen2026-07-17T06:58:00.000ZDIMERIX EXPANDS PIPELINE WITH ACQUISITION OF PHASE 2 READY ASSET FOR ACUTE KIDNEY INJURYhttps://www.pharmaradar360.com/article/does-zasocitinib-s-phase-3-success-in-hard-to-treat-psoriasis-areas-change-the-b-5a415b34d16ee3adPharma Surgeen2026-07-17T06:53:52.000ZDoes Zasocitinib’s Phase 3 Success in Hard-to-Treat Psoriasis Areas Change The Bull Case For Takeda Pharmaceutical (TSE:4502)?https://www.pharmaradar360.com/article/morning-briefing-biotech-growth-shareholders-signal-opposition-to-fund-manager-g-18e831669f7d47a8Pharma Surgeen2026-07-17T06:52:11.000ZMorning briefing: Biotech Growth shareholders signal opposition to fund manager Geoff Hsu's presence on the boardhttps://www.pharmaradar360.com/article/la-version-mise-a-jour-du-formulaire-de-demande-d-autorisation-de-mise-sur-le-ma-fc397c76f0cf22f6Pharma Surgeen2026-07-17T06:52:04.000ZLa version mise à jour du formulaire de demande d'autorisation de mise sur le marché est désormais disponible pour les procédures nationales, de reconnaissance mutuelle et décentraliséeshttps://www.pharmaradar360.com/article/biotech-growth-trust-portfolio-company-ataibeckley-to-be-acquired-by-eli-lilly-cf0db7612c931a38Pharma Surgeen2026-07-17T06:40:42.000ZBiotech Growth Trust Portfolio Company AtaiBeckley To Be Acquired By Eli Lillyhttps://www.pharmaradar360.com/article/biomarkers-in-nephrology-research-from-exploratory-to-decision-making-tools-2290c940259f3fc1Pharma Surgeen2026-07-17T06:33:45.000ZBiomarkers in Nephrology Research: From Exploratory to Decision-Making Toolshttps://www.pharmaradar360.com/article/annex-1-sterilisation-why-pharma-packaging-strategy-is-changing-d0874f189c71fd8bPharma Surgeen2026-07-17T06:33:45.000ZAnnex 1 sterilisation: Why pharma packaging strategy is changinghttps://www.pharmaradar360.com/article/gates-mri-serum-institute-of-india-sign-agreement-to-manufacture-tuberculosis-va-bd1656c40c414a4bPharma Surgeen2026-07-17T06:17:00.000ZGates MRI, Serum Institute of India sign agreement to manufacture Tuberculosis Vaccine candidatehttps://www.pharmaradar360.com/article/fda-accepts-resubmission-of-camurus-cam2029-nd-acf50a8147f34498Pharma Surgeen2026-07-17T05:56:16.000ZFDA accepts resubmission of Camurus' CAM2029 ND...https://www.pharmaradar360.com/article/west-wst-stock-looks-fair-on-cash-flow-yet-pricey-on-earnings-fc2502658d83384bPharma Surgeen2026-07-17T05:35:17.000ZWest (WST) Stock Looks Fair On Cash Flow Yet Pricey On Earningshttps://www.pharmaradar360.com/article/bio-asia-taiwan-2026-day-3-round-up-biotech-s-next-great-race-begins-where-disco-81f22e93b33d747bPharma Surgeen2026-07-17T05:29:29.000ZBIO Asia–Taiwan 2026 Day 3 Round-Up: Biotech’s Next Great Race Begins Where Discovery Endshttps://www.pharmaradar360.com/article/why-is-intellia-therapeutics-ntla-a-battleground-stock-with-38-short-interest-ac440ef295d82fe1Pharma Surgeen2026-07-17T05:11:20.000ZWhy is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interesthttps://www.pharmaradar360.com/article/world-syringes-for-agilent-market-analysis-forecast-size-trends-and-insights-8e6810dd2f824fffPharma Surgeen2026-07-17T04:51:13.000ZWorld Syringes for Agilent - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/reversing-ai-drug-discovery-belgian-biotech-sightera-raises-3m-to-learn-from-ext-b2815e249048e134Pharma Surgeen2026-07-17T04:00:34.000ZReversing AI drug discovery: Belgian biotech Sightera raises €3M to learn from 'extreme' patient biology firsthttps://www.pharmaradar360.com/article/propylene-glycol-usp-market-forecast-points-higher-toward-2035-driven-by-pharmac-0075cc6413e5c412Pharma Surgeen2026-07-17T03:26:12.000ZPropylene Glycol USP Market Forecast Points Higher Toward 2035, Driven by Pharmaceutical Excipient Demandhttps://www.pharmaradar360.com/article/shinsa-english-translation-of-review-report-riheart-f353dfdddfe8263dPharma Surgeen2026-07-17T03:00:00.000Z[SHINSA]English Translation of Review Report: RiHEARThttps://www.pharmaradar360.com/article/taiwan-s-biotech-ambition-gets-a-presidential-signal-as-vice-president-hsiao-bi-76d2d21c504bc23dPharma Surgeen2026-07-17T02:58:51.000ZTaiwan’s Biotech Ambition Gets a Presidential Signal as Vice President Hsiao Bi-khim Visits BIO Asia–Taiwan 2026https://www.pharmaradar360.com/article/etfs-investing-in-oneness-biotech-co-ltd-stocks-ee973db3a91d5108Pharma Surgeen2026-07-17T02:53:15.000ZETFs Investing in Oneness Biotech Co., Ltd. Stockshttps://www.pharmaradar360.com/article/top-biotech-gainers-cdna-soars-on-medicare-policy-atai-acquired-abt-lifts-outloo-42a59cac216a0496Pharma Surgeen2026-07-17T02:52:00.000ZTop Biotech Gainers: CDNA Soars On Medicare Policy, ATAI Acquired, ABT Lifts Outlook, APLM On Watchhttps://www.pharmaradar360.com/article/new-pharmaceutical-campus-coming-to-marion-will-further-educational-opportunitie-3830ecde5f847279Pharma Surgeen2026-07-17T01:00:00.000ZNew pharmaceutical campus coming to Marion; will further educational opportunities for ASU studentshttps://www.pharmaradar360.com/article/did-west-s-expanded-daikyo-distribution-deal-reshape-west-pharmaceutical-service-276320adf334967cPharma Surgeen2026-07-17T00:17:00.000ZDid West’s Expanded Daikyo Distribution Deal Reshape West Pharmaceutical Services' (WST) GLP‑1 Component Investment Narrative?https://www.pharmaradar360.com/article/gsk-filed-form-6-k-78ee3acd109f38b6Pharma Surgeen2026-07-17T00:00:00.000ZGSK filed Form 6-Khttps://www.pharmaradar360.com/article/sanofi-filed-form-6-k-38b5391da40c88ddPharma Surgeen2026-07-17T00:00:00.000ZSanofi filed Form 6-Khttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-25b0a819f9c1458aPharma Surgeen2026-07-17T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-24bc42ce9dbe3dcdPharma Surgeen2026-07-17T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-12c700d155bac7cdPharma Surgeen2026-07-17T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-eb5783e0703af792Pharma Surgeen2026-07-17T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-fe40761adb6748c1Pharma Surgeen2026-07-17T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-45cf4dd599048091Pharma Surgeen2026-07-17T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-d060d0f83b1662f9Pharma Surgeen2026-07-17T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-a051ca4aa25c93a4Pharma Surgeen2026-07-17T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-e83c942f88b483e0Pharma Surgeen2026-07-17T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-df9581853f129271Pharma Surgeen2026-07-17T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-fc125ae779d863f6Pharma Surgeen2026-07-17T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-60836779eb0d2615Pharma Surgeen2026-07-17T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-b8ed3598d7259c02Pharma Surgeen2026-07-17T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-6059ec1a65c791f5Pharma Surgeen2026-07-17T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-public-comment-requ-22a9ea239a8aef47Pharma Surgeen2026-07-17T00:00:00.000ZAgency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: National Practitioner Data Bank for Adverse Information on Physicians and Other Health Care Practitioners-45 CFR Part 60 Regulations and Forms, OMB No. 0906-0081-Revisionhttps://www.pharmaradar360.com/article/national-center-for-complementary-integrative-health-notice-of-meeting-78ddeab291738ed7Pharma Surgeen2026-07-17T00:00:00.000ZNational Center for Complementary & Integrative Health; Notice of Meetinghttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-acc-65561b53e7bd35dbPharma Surgeen2026-07-17T00:00:00.000ZAgency Information Collection Activities; Proposed Collection; Comment Request; Accreditation Scheme for Conformity Assessment Programhttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-adv-86860004be8ccac1Pharma Surgeen2026-07-17T00:00:00.000ZAgency Information Collection Activities; Proposed Collection; Comment Request; Adverse Event Program for Medical Devices: (Medical Product Safety Network (MedSun))https://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-inf-0fd07d7bbe69b004Pharma Surgeen2026-07-17T00:00:00.000ZAgency Information Collection Activities; Proposed Collection; Comment Request; Infant Formula Requirementshttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-med-03b98120c4322232Pharma Surgeen2026-07-17T00:00:00.000ZAgency Information Collection Activities; Proposed Collection; Comment Request; Medical Devices; Voluntary Improvement Programhttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-vol-192486c6c11b21a3Pharma Surgeen2026-07-17T00:00:00.000ZAgency Information Collection Activities; Proposed Collection; Comment Request; Voluntary National Retail Food Regulatory Program Standardshttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-req-0a6dbf37b076ebadPharma Surgeen2026-07-17T00:00:00.000ZAgency Information Collection Activities; Proposed Collection; Comment Request; Requirements for Cosmetic Productshttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-omb-review-comment-reque-714edd0b9db5bb65Pharma Surgeen2026-07-17T00:00:00.000ZAgency Information Collection Activities: Submission for OMB Review; Comment Requesthttps://www.pharmaradar360.com/article/clinical-epidemiological-and-spatial-profile-by-degree-of-physical-disability-in-097013f76f5332a9Pharma Surgeen2026-07-17T00:00:00.000ZClinical-Epidemiological and Spatial Profile by Degree of Physical Disability in Leprosy in the State of Pará, Brazilian Amazon (2013 to 2024): A Cross-Sectional Studyhttps://www.pharmaradar360.com/article/antifungal-sesquiterpens-8-epi-xanthatin-and-8-epixanthatin-1-5-epoxide-isolated-42fa445e0282c54ePharma Surgeen2026-07-17T00:00:00.000ZANTIFUNGAL SESQUITERPENS 8-EPI-XANTHATIN AND 8-EPIXANTHATIN-1, 5-EPOXIDE ISOLATED FROM LEAVES OF XANTHIUM STRUMARIUMhttps://www.pharmaradar360.com/article/effects-of-functional-training-on-body-composition-in-adults-with-overweight-or-08abf5a0ced8a64ePharma Surgeen2026-07-17T00:00:00.000ZEffects of Functional Training on Body Composition in Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis of Randomized Clinical Trialshttps://www.pharmaradar360.com/article/abdominal-wall-endometriosis-following-cesarean-section-a-retrospective-analysis-f7cf77cab5530c41Pharma Surgeen2026-07-17T00:00:00.000ZAbdominal Wall Endometriosis Following Cesarean Section: A Retrospective Analysishttps://www.pharmaradar360.com/article/computed-tomography-based-comparison-of-anterior-and-posterior-cortical-thicknes-cfd79f332a20fa7ePharma Surgeen2026-07-17T00:00:00.000ZComputed Tomography-Based Comparison of Anterior and Posterior Cortical Thickness Around the Interfragmentary Screw Fixation Level in Weber B Lateral Malleolar Fractureshttps://www.pharmaradar360.com/article/a-20-year-spatio-temporal-analysis-of-gender-workforce-in-medical-departments-of-247280618ba58cb6Pharma Surgeen2026-07-17T00:00:00.000ZA 20-Year Spatio-Temporal Analysis of Gender Workforce in Medical Departments of Psychiatry/Psychotherapy and Neurology in Germanyhttps://www.pharmaradar360.com/article/first-trimester-maternal-serum-growth-arrest-specific-protein-6-gas6-levels-for-d7e1f68a2687d1cfPharma Surgeen2026-07-17T00:00:00.000ZFirst-Trimester Maternal Serum Growth Arrest-Specific Protein 6 (Gas6) Levels for the Prediction of Preeclampsiahttps://www.pharmaradar360.com/article/lower-urinary-tract-symptoms-in-women-with-surgically-confirmed-endometriosis-as-29063b9ca564b58fPharma Surgeen2026-07-17T00:00:00.000ZLower Urinary Tract Symptoms in Women with Surgically Confirmed Endometriosis: Association with Urethral Ultrasonographic Findingshttps://www.pharmaradar360.com/article/sex-specific-association-between-serum-sod-activity-and-osteoporosis-in-type-2-d-9ec49788551ea6b9Pharma Surgeen2026-07-17T00:00:00.000ZSex-Specific Association Between Serum SOD Activity and Osteoporosis in Type 2 Diabetes: A Cross-Sectional Study with Functional Validationhttps://www.pharmaradar360.com/article/uncovering-patient-reported-and-observed-barriers-and-facilitators-to-sufficient-cb66070bb67040a8Pharma Surgeen2026-07-17T00:00:00.000ZUncovering Patient-Reported and Observed Barriers and Facilitators to Sufficient Dietary Intake in Acutely Admitted Older Adults: Insights from a Nutritional Trialhttps://www.pharmaradar360.com/article/crispr-cas9-in-cancer-therapy-clinical-translation-mechanistic-strategies-and-th-9f8f4551cae9383aPharma Surgeen2026-07-17T00:00:00.000ZCRISPR/Cas9 in cancer therapy: clinical translation, mechanistic strategies, and therapeutic directionshttps://www.pharmaradar360.com/article/effects-of-ketogenic-diet-therapy-in-outpatient-anti-epileptic-drug-cost-reducti-f7ecd5e8720baae8Pharma Surgeen2026-07-17T00:00:00.000ZEffects of ketogenic diet therapy in outpatient anti epileptic drug cost reduction and parental satisfaction among children with intractable epilepsyhttps://www.pharmaradar360.com/article/conceptualizing-and-treating-the-polytrauma-clinical-triad-as-a-complex-chronic-8ba03be5e6d80a6cPharma Surgeen2026-07-17T00:00:00.000ZConceptualizing and treating the polytrauma clinical triad as a complex chronic pain syndromehttps://www.pharmaradar360.com/article/vedolizumab-in-biologic-naive-ulcerative-colitis-a-multicenter-real-world-evalua-a04324aaad4c84dePharma Surgeen2026-07-17T00:00:00.000ZVedolizumab in biologic-naïve ulcerative colitis: a multicenter real-world evaluation of clinical benefits and exploratory inflammatory indiceshttps://www.pharmaradar360.com/article/toward-explainable-and-adaptive-artificial-intelligence-systems-for-antimicrobia-1bd80ca6b41e2c8bPharma Surgeen2026-07-17T00:00:00.000ZToward explainable and adaptive artificial intelligence systems for antimicrobial peptide discovery under resistance pressurehttps://www.pharmaradar360.com/article/efficacy-and-safety-of-acupuncture-for-coronary-microvascular-disease-study-prot-e539a194a71fd820Pharma Surgeen2026-07-17T00:00:00.000ZEfficacy and safety of acupuncture for coronary microvascular disease: study protocol for a pilot randomized controlled trialhttps://www.pharmaradar360.com/article/twenty-years-of-frontal-lobe-surgery-clinical-outcomes-and-lessons-from-the-fron-e2b5843edf2151cePharma Surgeen2026-07-17T00:00:00.000ZTwenty years of frontal lobe surgery: Clinical outcomes and lessons from the frontierhttps://www.pharmaradar360.com/article/temperature-excursion-risk-window-in-pharmaceutical-air-cargo-b4268d10e91edc9aPharma Surgeen2026-07-17T00:00:00.000ZTemperature Excursion Risk Window in Pharmaceutical Air Cargohttps://www.pharmaradar360.com/article/directory-of-open-access-journals-indexing-and-new-clinical-perspectives-in-the-0e507ec78d488e88Pharma Surgeen2026-07-17T00:00:00.000ZDirectory of Open Access Journals indexing and new clinical perspectives in the second issue of 2026https://www.pharmaradar360.com/article/clinical-hemato-biochemical-and-ultrasonographic-alterations-in-dogs-with-pancre-82db0f42fc26820cPharma Surgeen2026-07-17T00:00:00.000ZClinical, Hemato-biochemical and Ultrasonographic Alterations in Dogs with Pancreatitis and their Therapeutic Managementhttps://www.pharmaradar360.com/article/identifying-tmem127-deficient-pheochromocytomas-paragangliomas-via-ret-overexpre-54d50ed3a0953ff6Pharma Surgeen2026-07-17T00:00:00.000ZIdentifying TMEM127-deficient pheochromocytomas/paragangliomas via RET overexpression by immunohistochemistryhttps://www.pharmaradar360.com/article/symptom-oriented-clinical-psychiatry-495e10271aa81ebcPharma Surgeen2026-07-17T00:00:00.000ZSymptom-oriented clinical psychiatryhttps://www.pharmaradar360.com/article/cancer-stem-cells-and-drug-resistance-in-cancer-molecular-mechanisms-and-therape-2c972c34aa8af6fbPharma Surgeen2026-07-17T00:00:00.000ZCancer stem cells and drug resistance in cancer: molecular mechanisms and therapeutic targetshttps://www.pharmaradar360.com/article/tracheal-rhinoscleroma-clinical-endoscopic-and-radiological-features-in-a-five-p-b2a52ed6ebb4943ePharma Surgeen2026-07-17T00:00:00.000ZTracheal rhinoscleroma: clinical, endoscopic, and radiological features in a five-patient case series and literature reviewhttps://www.pharmaradar360.com/article/nigerian-medicinal-plants-on-the-road-to-drug-discovery-prospects-and-challenges-0c46b46f0856bd60Pharma Surgeen2026-07-17T00:00:00.000ZNigerian medicinal plants on the road to drug discovery: prospects and challengeshttps://www.pharmaradar360.com/article/work-life-spillover-clinical-decision-making-and-quality-of-care-in-nursing-the-ba562ba90776487bPharma Surgeen2026-07-17T00:00:00.000ZWork-life spillover, clinical decision-making, and quality of care in nursing: the role of negative interferencehttps://www.pharmaradar360.com/article/cbl-with-integrated-sdh-versus-cbl-alone-in-esophageal-surgery-internship-a-rand-a34930a1b70e6705Pharma Surgeen2026-07-17T00:00:00.000ZCBL with integrated SDH versus CBL alone in esophageal surgery internship: a randomized controlled trial on clinical competence developmenthttps://www.pharmaradar360.com/article/effect-of-framed-mhealth-messages-on-oral-hygiene-and-quality-of-life-among-suda-a09b120c67efc234Pharma Surgeen2026-07-17T00:00:00.000ZEffect of framed mHealth messages on oral hygiene and quality of life among Sudanese refugees in Egypt: a randomized controlled trialhttps://www.pharmaradar360.com/article/clinical-characteristics-and-associated-factors-of-post-infectious-bronchiolitis-f4ca7d53dd6c0e07Pharma Surgeen2026-07-17T00:00:00.000ZClinical characteristics and associated factors of post-infectious bronchiolitis obliterans in children with severe pneumonia and respiratory failure: a retrospective cohort studyhttps://www.pharmaradar360.com/article/study-protocol-of-the-c-solve-jaccro-gc-12-trial-a-randomized-non-comparative-ph-dd64102ee172172aPharma Surgeen2026-07-17T00:00:00.000ZStudy protocol of the C-SOLVE (JACCRO GC-12) trial; a randomized, non-comparative phase II trial of CapeOX or SOX plus zolbetuximab in HER2-negative, CLDN18.2-positive unresectable advanced gastric or esophagogastric junction cancerhttps://www.pharmaradar360.com/article/syne1-related-motor-neuron-disease-like-phenotype-with-mild-distal-contractures-f41be1eb2d2cafc1Pharma Surgeen2026-07-17T00:00:00.000ZSYNE1-Related motor neuron disease-like phenotype with mild distal contractures and 24-month clinical stability: a case reporthttps://www.pharmaradar360.com/article/clinical-characteristics-associated-with-severe-misdiagnosis-of-scabies-a-retros-8caa8a0959e6019aPharma Surgeen2026-07-17T00:00:00.000ZClinical characteristics associated with severe misdiagnosis of scabies: a retrospective hospital-based studyhttps://www.pharmaradar360.com/article/clinical-value-of-rt-3de-in-evaluating-mitral-valve-configuration-and-the-occurr-47b6e06f32ea36bePharma Surgeen2026-07-17T00:00:00.000ZClinical value of RT-3DE in evaluating mitral valve configuration and the occurrence of VFMR in patients with ischemic cardiomyopathy: a clinical investigationhttps://www.pharmaradar360.com/article/supplementary-figure-s1-from-preclinical-activity-of-the-b7-h3-targeting-antibod-d01ba96a7a89aa34Pharma Surgeen2026-07-17T00:00:00.000ZSupplementary Figure S1 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumorshttps://www.pharmaradar360.com/article/supplementary-figure-s3-from-preclinical-activity-of-the-b7-h3-targeting-antibod-3c53ae3831eb604aPharma Surgeen2026-07-17T00:00:00.000ZSupplementary Figure S3 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumorshttps://www.pharmaradar360.com/article/supplementary-table-s10-from-preclinical-activity-of-the-b7-h3-targeting-antibod-18e91b8ad1d7ea8dPharma Surgeen2026-07-17T00:00:00.000ZSupplementary Table S10 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumorshttps://www.pharmaradar360.com/article/supplementary-table-s11-from-preclinical-activity-of-the-b7-h3-targeting-antibod-d6af67ba4162416dPharma Surgeen2026-07-17T00:00:00.000ZSupplementary Table S11 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumorshttps://www.pharmaradar360.com/article/supplementary-table-s4-from-preclinical-activity-of-the-b7-h3-targeting-antibody-01e5fd5281bbf6d0Pharma Surgeen2026-07-17T00:00:00.000ZSupplementary Table S4 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumorshttps://www.pharmaradar360.com/article/supplementary-table-s7-from-preclinical-activity-of-the-b7-h3-targeting-antibody-01f7c0cc76953af5Pharma Surgeen2026-07-17T00:00:00.000ZSupplementary Table S7 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumorshttps://www.pharmaradar360.com/article/supplementary-figure-s2-from-gemcitabine-plus-nivolumab-with-carboplatin-or-oxal-349a281fe0c01620Pharma Surgeen2026-07-17T00:00:00.000ZSupplementary Figure S2 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trialhttps://www.pharmaradar360.com/article/supplementary-figure-s5-from-gemcitabine-plus-nivolumab-with-carboplatin-or-oxal-470d51ed21ae7eafPharma Surgeen2026-07-17T00:00:00.000ZSupplementary Figure S5 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trialhttps://www.pharmaradar360.com/article/supplementary-figure-s3-from-a-single-arm-phase-2-trial-of-doxorubicin-plus-zali-685e572884435db9Pharma Surgeen2026-07-17T00:00:00.000ZSupplementary Figure S3 from A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti–CTLA-4 Antibody) and Balstilimab (Anti–PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomashttps://www.pharmaradar360.com/article/epidemiology-of-children-and-young-people-presenting-to-australian-emergency-dep-5820d0d15b86357dPharma Surgeen2026-07-17T00:00:00.000ZEpidemiology of Children and Young People Presenting to Australian Emergency Departments for the Management of Acute Severe Behavioural Disturbance: Secondary Analysis of a Randomised Controlled Trialhttps://www.pharmaradar360.com/article/withania-somnifera-ashwagandha-as-an-adjunctive-treatment-to-antipsychotic-medic-60d72841f477cfc7Pharma Surgeen2026-07-17T00:00:00.000ZWithania somnifera (Ashwagandha) as an Adjunctive Treatment to Antipsychotic Medications for Patients With Schizophreniahttps://www.pharmaradar360.com/article/pemphigoid-was-not-associated-with-increased-risk-of-solid-organ-hematologic-or-e5757299f4a78a55Pharma Surgeen2026-07-17T00:00:00.000ZPemphigoid was not associated with increased risk of solid organ, hematologic, or nonmelanoma skin malignancies in a nationally representative matched cohorthttps://www.pharmaradar360.com/article/an-innovative-injection-technique-for-treating-edematous-fibrosclerotic-pannicul-d41234fd6f83921fPharma Surgeen2026-07-17T00:00:00.000ZAn Innovative Injection Technique for Treating Edematous Fibrosclerotic Panniculopathy (Cellulite): A Prospective Multicenter Clinical Investigationhttps://www.pharmaradar360.com/article/rotation-traction-manipulation-versus-cervical-traction-for-axial-neck-pain-caus-5c5f071792595a89Pharma Surgeen2026-07-17T00:00:00.000ZRotation-traction manipulation versus cervical traction for axial neck pain caused by cervical degenerative disc disease: a multicenter randomized controlled trialhttps://www.pharmaradar360.com/article/clinical-characteristics-treatment-and-prognosis-of-ixekizumab-induced-inflammat-8dd41184c8042812Pharma Surgeen2026-07-17T00:00:00.000ZClinical characteristics, treatment, and prognosis of ixekizumab-induced inflammatory bowel diseasehttps://www.pharmaradar360.com/article/innovative-applications-of-microbial-carotenoids-in-the-pharmaceutical-cosmetic-9221229cad02ee93Pharma Surgeen2026-07-17T00:00:00.000ZInnovative Applications of Microbial Carotenoids in the Pharmaceutical, Cosmetic, and Nutraceutical Sectorshttps://www.pharmaradar360.com/article/adopting-the-lancet-commission-definition-of-clinical-obesity-in-metabolic-dysfu-3530923835496922Pharma Surgeen2026-07-17T00:00:00.000ZAdopting the lancet commission definition of clinical obesity in metabolic dysfunction-associated steatotic liver disease (MASLD)https://www.pharmaradar360.com/article/isolated-congenital-eyelid-eversion-with-familial-occurrence-a-rare-clinical-ent-1a4dd61f637b8164Pharma Surgeen2026-07-17T00:00:00.000ZIsolated congenital eyelid eversion with familial occurrence: a rare clinical entityhttps://www.pharmaradar360.com/article/symptomatic-intracranial-hemorrhage-and-other-complications-with-tenecteplase-ve-b0a46f2a4abd6c84Pharma Surgeen2026-07-17T00:00:00.000ZSymptomatic Intracranial Hemorrhage and Other Complications with Tenecteplase Versus Alteplase in Acute Ischemic Stroke: A Systematic Review and Meta-analysishttps://www.pharmaradar360.com/article/not-all-screen-use-is-equal-shifting-the-focus-from-screen-time-to-problematic-u-21fa76a223966971Pharma Surgeen2026-07-17T00:00:00.000ZNot All Screen Use is Equal: Shifting the Focus from Screen Time to Problematic Use in Child and Adolescent Well-Being Researchhttps://www.pharmaradar360.com/article/hiv-related-stigma-in-people-living-with-hiv-a-cross-sectional-analysis-of-a-por-7e00a38da7626e24Pharma Surgeen2026-07-17T00:00:00.000ZHIV-Related Stigma in People Living with HIV: A Cross-Sectional Analysis of a Portuguese Clinical Cohorthttps://www.pharmaradar360.com/article/does-alternate-day-bathing-with-2-chlorhexidine-improve-clinical-outcomes-in-cri-1e518984ec1ab4e2Pharma Surgeen2026-07-17T00:00:00.000ZDoes alternate-day bathing with 2% chlorhexidine improve clinical outcomes in critically ill patients? A systematic review and meta-analysishttps://www.pharmaradar360.com/article/is-a-doctor-still-a-doctor-if-he-s-not-doctoring-reflections-on-a-life-of-doctor-e2bb8d17f6ff720cPharma Surgeen2026-07-17T00:00:00.000ZIs a doctor still a doctor if he’s not doctoring? Reflections on a life of doctoringhttps://www.pharmaradar360.com/article/diagnostic-accuracy-of-qraypen-fluorescence-scoring-for-secondary-caries-in-repa-3448708ddae03468Pharma Surgeen2026-07-17T00:00:00.000ZDiagnostic accuracy of QrayPen fluorescence scoring for secondary caries in repair-/replacement-indicated posterior composite restorationshttps://www.pharmaradar360.com/article/the-human-trophoblast-cell-surface-antigen-2-trop-2-expression-on-metastasized-b-ff723a5737303765Pharma Surgeen2026-07-17T00:00:00.000ZThe human trophoblast cell-surface antigen 2 (TROP-2) expression on metastasized breast cancerhttps://www.pharmaradar360.com/article/retinal-ischemic-perivascular-lesions-in-patients-with-pulmonary-embolism-an-oct-a694e2f5b0d10e66Pharma Surgeen2026-07-17T00:00:00.000ZRetinal ischemic perivascular lesions in patients with pulmonary embolism: an OCT angiography studyhttps://www.pharmaradar360.com/article/sub-tenon-s-triamcinolone-bridging-to-adalimumab-therapy-in-refractory-noninfect-cab78a50d0c7274fPharma Surgeen2026-07-17T00:00:00.000ZSub-Tenon’s triamcinolone bridging to adalimumab therapy in refractory noninfectious uveitic macular edemahttps://www.pharmaradar360.com/article/cathie-wood-is-loading-up-on-this-biotech-stock-is-it-a-no-brainer-buy-ad3bb0127554ec45Pharma Surgeen2026-07-16T23:51:17.000ZCathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy?https://www.pharmaradar360.com/article/is-this-biotech-stock-a-buy-near-its-52-week-high-0d7608874f80505dPharma Surgeen2026-07-16T23:37:30.000ZIs This Biotech Stock a Buy Near Its 52-Week High?https://www.pharmaradar360.com/article/dimerix-acquires-dmx-652-phase-2-asset-and-strengthens-kidney-disease-pipeline-w-3adb709d6de20136Pharma Surgeen2026-07-16T23:15:02.000ZDimerix Acquires DMX-652 Phase 2 Asset and Strengthens Kidney Disease Pipeline with Non-Dilutive Fundinghttps://www.pharmaradar360.com/article/compounded-glp-1s-why-doctors-worry-and-the-fda-is-cracking-down-ca1632ddd25cbc02Pharma Surgeen2026-07-16T23:06:38.000ZCompounded GLP-1s: Why doctors worry and the FDA is cracking downhttps://www.pharmaradar360.com/article/ups-commits-48-million-to-27-temperature-controlled-cross-dock-facilities-for-ph-1b8c4092b3d25cc8Pharma Surgeen2026-07-16T23:02:55.000ZUPS commits $48 million to 27 temperature-controlled cross-dock facilities for pharma and biotechhttps://www.pharmaradar360.com/article/telix-completes-patient-enrollment-in-tlx591-px-illuccix-japan-phase-3-study-652d771e46157df8Pharma Surgeen2026-07-16T22:15:22.000ZTelix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Studyhttps://www.pharmaradar360.com/article/lilly-offers-up-to-3-8-billion-for-ataibeckley-in-bet-on-god-molecule-found-in-t-a9777e5f3b8af372Pharma Surgeen2026-07-16T22:09:01.000ZLilly offers up to $3.8 billion for AtaiBeckley in bet on ‘God molecule’ found in toad venomhttps://www.pharmaradar360.com/article/kolon-tissuegene-slides-20-ahead-of-u-s-tg-c-phase-3-results-286461bd79ed3196Pharma Surgeen2026-07-16T22:00:05.000ZKolon TissueGene Slides 20% Ahead of U.S. TG-C Phase 3 Resultshttps://www.pharmaradar360.com/article/takeda-s-daily-pill-helped-clear-psoriasis-on-palms-and-soles-for-about-70-62e7b49ae0078a87Pharma Surgeen2026-07-16T22:00:00.000ZTakeda’s daily pill helped clear psoriasis on palms and soles for about 70%https://www.pharmaradar360.com/article/has-pfizer-s-seagen-acquisition-reshaped-the-oncology-landscape-6644d3994e5aa75cPharma Surgeen2026-07-16T21:33:52.000ZHas Pfizer's Seagen Acquisition Reshaped the Oncology Landscapehttps://www.pharmaradar360.com/article/drug-repurposing-stakeholders-say-fda-should-act-within-its-authority-avoid-disi-7d3efdd421815e8fPharma Surgeen2026-07-16T21:18:00.000ZDrug repurposing: Stakeholders say FDA should act within its authority, avoid disincentiveshttps://www.pharmaradar360.com/article/ubs-michael-yee-talks-biotech-m-a-outlook-61ef468ee07cec60Pharma Surgeen2026-07-16T21:08:11.000ZUBS Michael Yee talks biotech M&A outlookhttps://www.pharmaradar360.com/article/briacell-bctx-expands-phase-3-study-with-new-clinical-site-038c504f73cc5325Pharma Surgeen2026-07-16T20:48:45.000ZBriaCell (BCTX) Expands Phase 3 Study with New Clinical Sitehttps://www.pharmaradar360.com/article/gates-mri-serum-institute-sign-deal-to-manufacture-novel-tb-vaccine-candidate-0d19ba1784d81ee2Pharma Surgeen2026-07-16T20:09:11.000ZGates MRI, Serum Institute sign deal to manufacture novel TB vaccine candidatehttps://www.pharmaradar360.com/article/understanding-agentic-ai-in-clinical-development-ad4c832a0ca862a8Pharma Surgeen2026-07-16T20:01:06.000ZUnderstanding Agentic AI in Clinical Developmenthttps://www.pharmaradar360.com/article/houston-als-biotech-coya-eyes-2028-approval-path-0892964e5a2a9c85Pharma Surgeen2026-07-16T19:51:52.000ZHouston ALS Biotech Coya Eyes 2028 Approval Pathhttps://www.pharmaradar360.com/article/basis-kids-phase-3-trial-releases-encouraging-interim-data-on-marstacimab-for-he-98089931fb4c5642Pharma Surgeen2026-07-16T19:37:00.000ZBASIS KIDS Phase 3 Trial Releases Encouraging Interim Data on Marstacimab for Hemophilia A, Bhttps://www.pharmaradar360.com/article/kalshi-is-letting-people-bet-on-clinical-trials-and-fda-drug-decisions-373241bf22f43a54Pharma Surgeen2026-07-16T19:04:21.000ZKalshi Is Letting People Bet On Clinical Trials And FDA Drug Decisionshttps://www.pharmaradar360.com/article/this-biotech-stock-nearly-doubled-in-value-today-morning-what-s-driving-investor-2b6d85a1f88a0aebPharma Surgeen2026-07-16T18:53:28.000ZThis Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism?https://www.pharmaradar360.com/article/news-capricor-signs-san-diego-s-largest-biotech-lease-of-the-year-ac18b9e808e46fa7Pharma Surgeen2026-07-16T18:49:04.000ZNews | Capricor signs San Diego’s largest biotech lease of the yearhttps://www.pharmaradar360.com/article/fda-approves-lipfendra-pharmexec-4549d309a34b6dbcPharma Surgeen2026-07-16T18:43:45.000ZFDA Approves Lipfendra | PharmExechttps://www.pharmaradar360.com/article/hygiene-safety-lapses-in-production-area-fda-suspends-licence-of-south-mumbai-s-c75ecd40c50fa2caPharma Surgeen2026-07-16T18:42:21.000Z‘Hygiene, safety lapses in production area’: FDA suspends licence of South Mumbai’s iconic 110-year-old Parsi Dairy Farmhttps://www.pharmaradar360.com/article/sii-gates-mri-ink-pact-to-manufacture-new-tb-vaccine-candidate-after-successful-ae8691ced3fc9cb8Pharma Surgeen2026-07-16T18:36:00.000ZSII & Gates MRI ink pact to manufacture new TB vaccine candidate after successful Phase 3 trialshttps://www.pharmaradar360.com/article/serum-institute-gates-medical-research-institute-partners-to-manufacture-new-tb-54a03d60b234d52aPharma Surgeen2026-07-16T18:33:08.000ZSerum Institute, Gates Medical Research Institute partners to manufacture new TB vaccinehttps://www.pharmaradar360.com/article/eli-lilly-acquires-psychedelics-specialist-ataibeckley-what-investors-should-kno-2a8b87a7229db9dbPharma Surgeen2026-07-16T18:07:18.000ZEli Lilly Acquires Psychedelics Specialist AtaiBeckley - What Investors Should Know (LLY)https://www.pharmaradar360.com/article/nobel-laureate-jennifer-doudna-enters-ai-protein-design-arena-e48311cb4610afbaPharma Surgeen2026-07-16T18:00:00.000ZNobel Laureate Jennifer Doudna enters AI protein design arenahttps://www.pharmaradar360.com/article/eli-lilly-buys-psychedelics-maker-atai-beckley-for-2-8-billion-to-develop-dmt-li-daa99f5d7e338befPharma Surgeen2026-07-16T17:53:41.000ZEli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drughttps://www.pharmaradar360.com/article/mid-year-check-in-will-pharma-m-a-keep-pace-af840a02a921e2a5Pharma Surgeen2026-07-16T17:49:54.000ZMid-Year Check-In: Will Pharma M&A Keep Pace?https://www.pharmaradar360.com/article/iqvia-seeks-faster-path-from-discovery-to-human-drug-trials-ac1b1aa53332cdcaPharma Surgeen2026-07-16T17:39:00.000ZIQVIA Seeks Faster Path From Discovery to Human Drug Trialshttps://www.pharmaradar360.com/article/novo-secures-european-approval-for-oral-wegovy-to-extend-lead-over-lilly-b94013c2f0b84f44Pharma Surgeen2026-07-16T17:14:31.000ZNovo secures European approval for oral Wegovy to extend lead over Lillyhttps://www.pharmaradar360.com/article/eli-lilly-changed-depression-care-with-prozac-now-it-s-betting-on-psychedelics-w-94b48de695d030ecPharma Surgeen2026-07-16T17:13:02.000ZEli Lilly Changed Depression Care With Prozac. Now It's Betting on Psychedelics with AtaiBeckley Acquisitionhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-expands-daikyo-ties-as-valuation-questions-grow-2effc737c39088a9Pharma Surgeen2026-07-16T17:12:40.000ZWest Pharmaceutical Services (WST) Expands Daikyo Ties As Valuation Questions Growhttps://www.pharmaradar360.com/article/us-biotech-secures-150m-to-develop-potential-treatments-for-parkinson-s-d3f4907b60a56036Pharma Surgeen2026-07-16T17:09:56.000ZUS biotech secures $150M to develop potential treatments for Parkinson’shttps://www.pharmaradar360.com/article/uk-commits-to-pharma-ip-protection-in-swiss-trade-deal-4ee19ce62b080523Pharma Surgeen2026-07-16T17:04:58.000ZUK commits to pharma IP protection in Swiss trade dealhttps://www.pharmaradar360.com/article/lilly-enters-psychedelic-realm-through-2-8bn-ataibeckley-takeover-04eba4124fe4b3cfPharma Surgeen2026-07-16T17:04:58.000ZLilly enters psychedelic realm through $2.8bn AtaiBeckley takeoverhttps://www.pharmaradar360.com/article/kalshi-expands-into-biotech-with-markets-on-clinical-trials-fda-drug-approvals-ee0b93edbfa68ad9Pharma Surgeen2026-07-16T16:49:25.000ZKalshi Expands Into Biotech With Markets on Clinical Trials, FDA Drug Approvalshttps://www.pharmaradar360.com/article/children-s-health-further-protected-with-energy-drinks-ban-39335488dabc100aPharma Surgeen2026-07-16T16:39:49.000ZChildren’s health further protected with energy drinks banhttps://www.pharmaradar360.com/article/what-the-fda-s-pharma-ad-rule-could-mean-for-digital-and-creators-74ecd3a9d91fa7c2Pharma Surgeen2026-07-16T16:12:41.000ZWhat the FDA’s pharma ad rule could mean for digital and creatorshttps://www.pharmaradar360.com/article/merck-foundation-launches-community-collaborative-for-reimagining-hiv-care-to-ad-0211fe714f18616dPharma Surgeen2026-07-16T16:00:08.000ZMerck Foundation Launches Community Collaborative for Reimagining HIV Care to Advance Access to High-Quality HIV Care in U.S. Communitieshttps://www.pharmaradar360.com/article/capital-remains-selective-in-barbell-biotech-market-e49fca2ce6a8c914Pharma Surgeen2026-07-16T16:00:00.000ZCapital remains selective in ‘barbell’ biotech markethttps://www.pharmaradar360.com/article/pharmaceutical-company-cuts-energy-use-and-achieves-iso-compliance-with-compress-3dcf7713dd723262Pharma Surgeen2026-07-16T15:56:10.000ZPharmaceutical company cuts energy use and achieves ISO compliance with compressor and dryer upgradehttps://www.pharmaradar360.com/article/moneymasters-podcast-where-to-invest-now-in-ai-biotech-small-caps-gold-c7bea3639715272cPharma Surgeen2026-07-16T15:56:10.000ZMoneyMasters Podcast: Where to Invest NOW in AI, Biotech, Small Caps, & Gold!https://www.pharmaradar360.com/article/banning-the-sale-of-high-caffeine-energy-drinks-to-children-2dd4d499a8a92623Pharma Surgeen2026-07-16T15:40:59.000ZBanning the sale of high-caffeine energy drinks to childrenhttps://www.pharmaradar360.com/article/promising-phase-2-and-3-influenza-therapies-what-pharmacists-should-know-6a9b0cec67f1c6f5Pharma Surgeen2026-07-16T15:37:27.000ZPromising Phase 2 and 3 Influenza Therapies: What Pharmacists Should Knowhttps://www.pharmaradar360.com/article/annual-flu-programme-8d7750db1c23f662Pharma Surgeen2026-07-16T15:35:39.000ZAnnual flu programmehttps://www.pharmaradar360.com/article/drofen-publishes-second-column-in-pharmaceutical-technology-launches-pen-injecto-cc10f29402c690a5Pharma Surgeen2026-07-16T15:33:00.000ZDROFEN Publishes Second Column in Pharmaceutical Technology, Launches Pen Injector Pre-Assembly Machinehttps://www.pharmaradar360.com/article/air-cooling-and-filtration-the-critical-utilities-behind-sterile-pharmaceutical-01cef57301d87e2aPharma Surgeen2026-07-16T15:31:09.000ZAir, cooling and filtration: The critical utilities behind sterile pharmaceutical productionhttps://www.pharmaradar360.com/article/physical-activity-guidelines-children-and-young-people-5-to-18-years-eb1510c88ccd3c58Pharma Surgeen2026-07-16T15:19:32.000ZPhysical activity guidelines: children and young people (5 to 18 years)https://www.pharmaradar360.com/article/physical-activity-guidelines-disabled-adults-e5b4126ee40a356bPharma Surgeen2026-07-16T15:19:26.000ZPhysical activity guidelines: disabled adultshttps://www.pharmaradar360.com/article/physical-activity-guidelines-pregnancy-and-after-childbirth-195d2b08fdc77ffbPharma Surgeen2026-07-16T15:19:18.000ZPhysical activity guidelines: pregnancy and after childbirthhttps://www.pharmaradar360.com/article/physical-activity-guidelines-early-years-under-5s-93de9a428b7393ffPharma Surgeen2026-07-16T15:19:12.000ZPhysical activity guidelines: early years (under 5s)https://www.pharmaradar360.com/article/banta-and-tooman-argue-strategic-questioning-improves-pharmaceutical-decision-ma-0a21e35c62e06ba2Pharma Surgeen2026-07-16T15:19:10.000ZBanta and Tooman Argue Strategic Questioning Improves Pharmaceutical Decision-Making and AI Integrationhttps://www.pharmaradar360.com/article/physical-activity-guidelines-adults-and-older-adults-24dfd3484d3377c6Pharma Surgeen2026-07-16T15:19:07.000ZPhysical activity guidelines: adults and older adultshttps://www.pharmaradar360.com/article/dhsc-public-appointments-2026-to-2027-92f3e9c4047ba1dcPharma Surgeen2026-07-16T14:59:16.000ZDHSC public appointments: 2026 to 2027https://www.pharmaradar360.com/article/illumina-ordered-to-recall-products-after-german-patent-ruling-26ea60785aad2c2dPharma Surgeen2026-07-16T14:59:04.000ZIllumina ordered to recall products after German patent rulinghttps://www.pharmaradar360.com/article/merck-s-lipfendra-becomes-first-oral-cholesterol-pill-to-match-injectable-pcsk9-560d0d60e54792ebPharma Surgeen2026-07-16T14:49:34.000ZMerck’s Lipfendra Becomes First Oral Cholesterol Pill to Match Injectable PCSK9 Potencyhttps://www.pharmaradar360.com/article/environmental-monitoring-following-the-grenfell-tower-fire-85d5cc3f2b36adbcPharma Surgeen2026-07-16T14:48:19.000ZEnvironmental monitoring following the Grenfell Tower firehttps://www.pharmaradar360.com/article/ofsted-and-care-quality-commission-shared-principles-for-local-government-reorga-0c60e32ff27e8b20Pharma Surgeen2026-07-16T14:47:58.000ZOfsted and Care Quality Commission: shared principles for local government reorganisationhttps://www.pharmaradar360.com/article/us-zinc-prices-hold-steady-in-early-july-as-pharmaceutical-demand-and-supply-cos-5584fb890ab6b4dfPharma Surgeen2026-07-16T14:44:38.000ZUS Zinc Prices Hold Steady in Early July as Pharmaceutical Demand and Supply Costs Support Markethttps://www.pharmaradar360.com/article/what-does-briacell-s-latest-offering-mean-for-shareholders-0945e6fa4f984948Pharma Surgeen2026-07-16T14:34:49.000ZWhat Does BriaCell's Latest Offering Mean for Shareholdershttps://www.pharmaradar360.com/article/eli-lilly-lly-stock-dips-following-2-8b-ataibeckley-acquisition-for-depression-t-9014bf7a43d6c340Pharma Surgeen2026-07-16T14:20:40.000ZEli Lilly (LLY) Stock Dips Following $2.8B AtaiBeckley Acquisition for Depression Treatment Pipelinehttps://www.pharmaradar360.com/article/what-just-happened-with-generate-biomedicines-ipo-0cd87ba198a9481ePharma Surgeen2026-07-16T14:06:20.000ZWhat Just Happened with Generate Biomedicines' IPOhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-earnings-expected-to-grow-what-to-know-ahead-of-dbba3f846b2f69dePharma Surgeen2026-07-16T14:00:13.000ZWest Pharmaceutical Services (WST) Earnings Expected to Grow: What to Know Ahead of Next Week's Releasehttps://www.pharmaradar360.com/article/lab-monkey-prices-soar-as-china-s-biotech-boom-fuels-windfall-for-breeders-ad9d898c55efbfc2Pharma Surgeen2026-07-16T14:00:06.000ZLab monkey prices soar as China’s biotech boom fuels windfall for breedershttps://www.pharmaradar360.com/article/how-lilly-s-ataibeckley-deal-accelerates-psychedelic-drug-commercialization-push-3caa77dc9d695042Pharma Surgeen2026-07-16T13:59:54.000ZHow Lilly's AtaiBeckley Deal Accelerates Psychedelic Drug Commercialization Pushhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-nkgen-biotech-inc-otc-nkgnw-37301e8376acdf7aPharma Surgeen2026-07-16T13:53:06.000ZPrice to earnings forward of NKGen Biotech Inc. – OTC:NKGNWhttps://www.pharmaradar360.com/article/briacell-bctx-expands-phase-3-study-with-new-clinical-site-345833b72b3b95fdPharma Surgeen2026-07-16T13:41:15.000ZBriaCell (BCTX) Expands Phase 3 Study with New Clinical Sitehttps://www.pharmaradar360.com/article/racing-takeda-innocare-reports-tyk2-inhibitor-win-in-phase-2-vitiligo-trial-d054c4619838ffa0Pharma Surgeen2026-07-16T13:36:42.000ZRacing Takeda, InnoCare reports TYK2 inhibitor win in phase 2 vitiligo trialhttps://www.pharmaradar360.com/article/care-workforce-pathway-for-adult-social-care-7c0f06f49dc43fcbPharma Surgeen2026-07-16T13:30:06.000ZCare workforce pathway for adult social carehttps://www.pharmaradar360.com/article/manufacturer-agreed-for-the-m72-tb-vaccine-candidate-news-b646948feeb416c0Pharma Surgeen2026-07-16T13:27:56.000ZManufacturer agreed for the M72 TB vaccine candidate | Newshttps://www.pharmaradar360.com/article/electronic-prescription-service-the-battle-for-nominations-ad58ea373822f6e4Pharma Surgeen2026-07-16T13:27:05.000ZElectronic prescription service: the battle for nominationshttps://www.pharmaradar360.com/article/jcvi-publishes-new-recommendation-to-government-on-adolescent-menb-vaccination-2c034385dd8837fbPharma Surgeen2026-07-16T13:25:31.000ZJCVI publishes new recommendation to Government on adolescent MenB vaccinationhttps://www.pharmaradar360.com/article/merck-dives-into-cholesterol-with-first-fda-approval-for-oral-pcsk9-inhibitor-b9235d486fcd89b9Pharma Surgeen2026-07-16T13:22:28.000ZMerck dives into cholesterol with first FDA approval for oral PCSK9 inhibitorhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-newland-pharmaceutical-co-ltd-class-a-szse-3-efb16c2b0d9d8816Pharma Surgeen2026-07-16T13:20:38.000ZEnterprise value to EBIT forward of Newland Pharmaceutical Co., Ltd. Class A – SZSE:301277https://www.pharmaradar360.com/article/pharmalittle-we-re-reading-about-kalshi-bets-on-clinical-trials-a-merck-choleste-a46031c4fc58af05Pharma Surgeen2026-07-16T13:15:51.000ZPharmalittle: We're reading about Kalshi bets on clinical trials, a Merck cholesterol pill, and morehttps://www.pharmaradar360.com/article/kalshi-launches-biotech-prediction-markets-pilot-program-c9237e46fc1efbaePharma Surgeen2026-07-16T13:15:43.000ZKalshi launches biotech prediction markets pilot programhttps://www.pharmaradar360.com/article/biotech-venture-funding-roars-back-272491de7fff8b98Pharma Surgeen2026-07-16T13:14:29.000ZBiotech Venture Funding Roars Backhttps://www.pharmaradar360.com/article/has-ocugen-s-recent-convertible-notes-offering-stabilized-its-financial-future-24b60403ee69b13dPharma Surgeen2026-07-16T13:06:54.000ZHas Ocugen's Recent Convertible Notes Offering Stabilized Its Financial Futurehttps://www.pharmaradar360.com/article/fda-approves-merck-s-oral-pcsk9-drug-a-first-da9c830b9ab8cf4fPharma Surgeen2026-07-16T13:06:07.000ZFDA approves Merck’s oral PCSK9 drug, a firsthttps://www.pharmaradar360.com/article/lilly-to-acquire-ataibeckley-99e62e8d5feb3906Pharma Surgeen2026-07-16T13:01:21.000ZLilly to Acquire AtaiBeckleyhttps://www.pharmaradar360.com/article/syndromic-surveillance-weekly-summaries-for-2026-45747e3878253defPharma Surgeen2026-07-16T13:00:03.000ZSyndromic surveillance: weekly summaries for 2026https://www.pharmaradar360.com/article/remote-health-advice-weekly-bulletins-for-2026-0b8fbceac342c05cPharma Surgeen2026-07-16T13:00:03.000ZRemote health advice: weekly bulletins for 2026https://www.pharmaradar360.com/article/national-ambulance-syndromic-surveillance-weekly-bulletins-2026-6dee157afd1fba75Pharma Surgeen2026-07-16T13:00:03.000ZNational ambulance syndromic surveillance: weekly bulletins 2026https://www.pharmaradar360.com/article/gp-out-of-hours-syndromic-surveillance-weekly-bulletins-for-2026-f212a5a75078c06ePharma Surgeen2026-07-16T13:00:03.000ZGP out-of-hours syndromic surveillance: weekly bulletins for 2026https://www.pharmaradar360.com/article/gp-in-hours-weekly-bulletins-for-2026-dfebf391f225843dPharma Surgeen2026-07-16T13:00:03.000ZGP in-hours: weekly bulletins for 2026https://www.pharmaradar360.com/article/emergency-department-weekly-bulletins-for-2026-08abcdde2881ef86Pharma Surgeen2026-07-16T13:00:03.000ZEmergency department: weekly bulletins for 2026https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-2026-to-2027-46b78a2386536090Pharma Surgeen2026-07-16T13:00:02.000ZWeekly all-cause mortality surveillance: 2026 to 2027https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-reports-2026-to-2027-season-32f74fa23fd23c69Pharma Surgeen2026-07-16T13:00:02.000ZNational flu and COVID-19 surveillance reports: 2026 to 2027 seasonhttps://www.pharmaradar360.com/article/jcvi-statement-on-meningococcal-b-vaccination-in-older-children-and-young-adults-26c1361f3a11f5e2Pharma Surgeen2026-07-16T13:00:02.000ZJCVI statement on meningococcal B vaccination in older children and young adults, 16 July 2026https://www.pharmaradar360.com/article/covid-19-vaccination-in-autumn-2027-jcvi-advice-14ee41f243122ef5Pharma Surgeen2026-07-16T13:00:02.000ZCOVID-19 vaccination in autumn 2027: JCVI advicehttps://www.pharmaradar360.com/article/plans-for-fair-pay-agreements-in-adult-social-care-easy-read-8df471110bb66761Pharma Surgeen2026-07-16T13:00:02.000ZPlans for fair pay agreements in adult social care (easy read)https://www.pharmaradar360.com/article/fair-pay-agreement-process-in-adult-social-care-15dd92c98eb8b8ffPharma Surgeen2026-07-16T13:00:02.000ZFair pay agreement process in adult social carehttps://www.pharmaradar360.com/article/all-cause-mortality-surveillance-8e78ac3be4ec1572Pharma Surgeen2026-07-16T13:00:02.000ZAll-cause mortality surveillancehttps://www.pharmaradar360.com/article/flu-vaccines-2027-to-2028-jcvi-advice-16-july-2026-c0a1820d73e3a4a7Pharma Surgeen2026-07-16T13:00:00.000ZFlu vaccines 2027 to 2028: JCVI advice, 16 July 2026https://www.pharmaradar360.com/article/medtronic-completes-acquisition-of-spr-expanding-patient-access-to-minimally-inv-09db69210d9d2676Pharma Surgeen2026-07-16T13:00:00.000ZMedtronic completes acquisition of SPR, expanding patient access to minimally invasive, non-opioid treatment of chronic and acute painhttps://www.pharmaradar360.com/article/cmps-stock-rises-23-pre-market-as-compass-achieves-primary-endpoint-in-phase-3-t-4191aa06fc271c3ePharma Surgeen2026-07-16T12:42:22.000ZCMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trialhttps://www.pharmaradar360.com/article/breaking-world-s-largest-pharmaceutical-company-eli-lilly-acquires-5-meo-dmt-dev-caeb382d220c4672Pharma Surgeen2026-07-16T12:41:35.000ZBreaking: World’s Largest Pharmaceutical Company, Eli Lilly, Acquires 5-MeO-DMT Developer AtaiBeckley for Up to $3.8 billionhttps://www.pharmaradar360.com/article/what-does-vir-biotechnology-s-astellas-deal-mean-for-its-future-d785696a0fbf1036Pharma Surgeen2026-07-16T12:38:48.000ZWhat Does Vir Biotechnology's Astellas Deal Mean for Its Futurehttps://www.pharmaradar360.com/article/eli-lilly-confirms-rumors-makes-a-bid-for-ataibeckley-0dcedc44e4f055f6Pharma Surgeen2026-07-16T12:30:25.000ZEli Lilly confirms rumors: Makes a bid for AtaiBeckleyhttps://www.pharmaradar360.com/article/decision-orphan-registered-medicinal-products-94c6c1735397020aPharma Surgeen2026-07-16T12:26:24.000ZDecision: Orphan registered medicinal productshttps://www.pharmaradar360.com/article/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metas-4e9827b67b758c59Pharma Surgeen2026-07-16T12:23:34.000ZBriaCell Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancerhttps://www.pharmaradar360.com/article/aspen-reaches-more-than-920-000-beneficiaries-through-mandela-day-cffe06c33b5b990aPharma Surgeen2026-07-16T12:22:37.000ZAspen reaches more than 920 000 beneficiaries through Mandela Dayhttps://www.pharmaradar360.com/article/lilly-to-acquire-ataibeckley-in-up-to-3-8-billion-mental-health-deal-e5c7bad82c425134Pharma Surgeen2026-07-16T12:14:09.000ZLilly to Acquire AtaiBeckley in Up to $3.8 Billion Mental Health Dealhttps://www.pharmaradar360.com/article/kalshi-expands-into-biotech-with-clinical-trial-wagers-by-investing-com-1b7b3694357e7ed4Pharma Surgeen2026-07-16T12:11:37.000ZKalshi expands into biotech with clinical trial wagers By Investing.comhttps://www.pharmaradar360.com/article/kalshi-expands-into-biotech-with-clinical-trial-wagers-84e8ad47f5b4528dPharma Surgeen2026-07-16T12:10:08.000ZKalshi expands into biotech with clinical trial wagershttps://www.pharmaradar360.com/article/pharma-pulse-cvs-credits-trumprx-to-deductibles-germany-hikes-drug-rebates-fd4ce7d829603cd0Pharma Surgeen2026-07-16T12:09:49.000ZPharma Pulse: CVS Credits TrumpRx to Deductibles, Germany Hikes Drug Rebateshttps://www.pharmaradar360.com/article/la-aemps-informa-de-un-posible-fallo-en-la-aplicacion-minimed-go-para-la-diabete-539fe29529fdc65bPharma Surgeen2026-07-16T12:09:32.000ZLa AEMPS informa de un posible fallo en la aplicación MiniMed Go para la diabetes que afecta al funcionamiento de las alertas nocturnashttps://www.pharmaradar360.com/article/kalshi-comes-for-biopharma-with-prediction-markets-for-clinical-trials-and-fda-a-013c3406002f76c5Pharma Surgeen2026-07-16T12:01:07.000ZKalshi comes for biopharma, with prediction markets for clinical trials and FDA approvalshttps://www.pharmaradar360.com/article/life-changing-ms-drugs-to-stay-on-the-pbs-so-why-are-others-under-threat-and-how-c896dd1fcb9b1a57Pharma Surgeen2026-07-16T12:01:00.000ZLife-changing MS drugs to stay on the PBS. So why are others under threat – and how is Trump involved?https://www.pharmaradar360.com/article/v-loctm-90-and-180-suture-products-52fb46049f9fafa7Pharma Surgeen2026-07-16T12:00:00.000ZV-Loc™ 90 and 180 Suture Productshttps://www.pharmaradar360.com/article/strykeflow-ps-and-ahto-ce836196a5199121Pharma Surgeen2026-07-16T12:00:00.000ZStrykeFlow PS and AHTOhttps://www.pharmaradar360.com/article/solartm-gi-dae44a3754bab86cPharma Surgeen2026-07-16T12:00:00.000ZSolar™ GIhttps://www.pharmaradar360.com/article/sema-3-b7832afdb64b9c9fPharma Surgeen2026-07-16T12:00:00.000ZSEMA 3https://www.pharmaradar360.com/article/kalshi-will-offer-sports-style-betting-on-drug-trial-results-204099a71093e481Pharma Surgeen2026-07-16T12:00:00.000ZKalshi Will Offer Sports-Style Betting on Drug Trial Resultshttps://www.pharmaradar360.com/article/grifols-trial-could-expand-treatment-options-for-60-000-patients-d3a4b6925cf2cd6aPharma Surgeen2026-07-16T12:00:00.000ZGrifols Trial Could Expand Treatment Options for 60,000 Patientshttps://www.pharmaradar360.com/article/tavneos-avacopan-07a6eea404db70c3Pharma Surgeen2026-07-16T11:45:32.000ZTavneos (avacopan): Απευθείας επικοινωνία προς επαγγελματίες υγείαςhttps://www.pharmaradar360.com/article/vegan-pdrn-is-reshaping-regenerative-skincare-as-biotech-alternatives-gain-momen-d80c7a4013b8b693Pharma Surgeen2026-07-16T11:37:24.000ZVegan PDRN Is Reshaping Regenerative Skincare as Biotech Alternatives Gain Momentumhttps://www.pharmaradar360.com/article/eli-lilly-to-acquire-psychedelics-focused-biotech-ataibeckley-ea922cb5f0ed02aePharma Surgeen2026-07-16T11:35:33.000ZEli Lilly to acquire psychedelics-focused biotech AtaiBeckleyhttps://www.pharmaradar360.com/article/lilly-buys-ataibeckley-for-2-8b-upfront-to-challenge-j-j-for-psychedelic-mental-582006a5d22f1f36Pharma Surgeen2026-07-16T11:32:42.000ZLilly buys AtaiBeckley for $2.8B upfront to challenge J&J for psychedelic mental health markethttps://www.pharmaradar360.com/article/sandoz-reshapes-leadership-to-capitalise-on-biosimilar-golden-decade-175ac7c0e324e450Pharma Surgeen2026-07-16T11:31:12.000ZSandoz reshapes leadership to capitalise on biosimilar golden decadehttps://www.pharmaradar360.com/article/nature-medicine-features-briacell-trial-among-11-that-will-shape-medicine-64194b54bb969718Pharma Surgeen2026-07-16T11:30:00.000ZNature Medicine Features BriaCell Trial Among 11 That Will Shape Medicinehttps://www.pharmaradar360.com/article/briacell-opens-first-canadian-site-sunnybrook-for-pivotal-phase-3-trial-in-metas-780cc9a1b9dc4040Pharma Surgeen2026-07-16T11:30:00.000ZBriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancerhttps://www.pharmaradar360.com/article/russian-reference-standards-centre-expands-into-pharmaceutical-wholesale-and-sto-a5defe6d27895847Pharma Surgeen2026-07-16T11:19:40.000ZRussian reference standards centre expands into pharmaceutical wholesale and storagehttps://www.pharmaradar360.com/article/eli-lilly-buys-psychedelic-biotech-backed-by-peter-thiel-ada260ea5506af7cPharma Surgeen2026-07-16T11:13:25.000ZEli Lilly buys psychedelic biotech backed by Peter Thielhttps://www.pharmaradar360.com/article/single-use-sterile-bioprocessing-tools-36e8ca0c44048cc5Pharma Surgeen2026-07-16T11:09:47.000ZSingle-Use Sterile Bioprocessing Toolshttps://www.pharmaradar360.com/article/single-use-sterile-bioprocessing-tools-2e820dff4d0ef8b6Pharma Surgeen2026-07-16T11:09:46.000ZSingle-Use Sterile Bioprocessing Toolshttps://www.pharmaradar360.com/article/relmada-therapeutics-to-report-second-quarter-2026-financial-results-on-thursday-ac8232b26f2a9208Pharma Surgeen2026-07-16T11:05:00.000ZRelmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026https://www.pharmaradar360.com/article/european-biotech-act-advances-biotechnology-innovation-5a48e492d66c07caPharma Surgeen2026-07-16T11:03:07.000ZEuropean Biotech Act Advances Biotechnology Innovationhttps://www.pharmaradar360.com/article/fedex-life-sciences-launches-to-support-pharmaceutical-logistics-eb60a6b5c3d54a1cPharma Surgeen2026-07-16T11:00:11.000ZFedEx Life Sciences launches to support pharmaceutical logisticshttps://www.pharmaradar360.com/article/moderna-trial-tests-cancer-therapy-encoding-seven-antigens-bbd9868fc112b037Pharma Surgeen2026-07-16T11:00:00.000ZModerna Trial Tests Cancer Therapy Encoding Seven Antigenshttps://www.pharmaradar360.com/article/immunoglobulin-when-to-use-2bc3407cfc7e587bPharma Surgeen2026-07-16T10:55:41.000ZImmunoglobulin: when to usehttps://www.pharmaradar360.com/article/eli-lilly-to-buy-psychedelics-maker-ataibeckley-for-2-8-billion-as-experimental-c83ccd6c6c9de6e5Pharma Surgeen2026-07-16T10:45:53.000ZEli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain tractionhttps://www.pharmaradar360.com/article/merck-s-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibit-f513ffd9e62e44adPharma Surgeen2026-07-16T10:45:00.000ZMerck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemiahttps://www.pharmaradar360.com/article/ataibeckley-s-bpl-003-shows-months-of-effects-after-2-hour-visits-c7ddce453dd42815Pharma Surgeen2026-07-16T10:45:00.000ZAtaiBeckley’s BPL-003 Shows Months of Effects After 2-Hour Visitshttps://www.pharmaradar360.com/article/lilly-to-acquire-ataibeckley-to-advance-therapies-for-treatment-resistant-depres-52ec112919ea8e7ePharma Surgeen2026-07-16T10:45:00.000ZLilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditionshttps://www.pharmaradar360.com/article/lilly-to-acquire-ataibeckley-to-advance-therapies-for-treatment-resistant-depres-f3af133918fbe32cPharma Surgeen2026-07-16T10:45:00.000ZLilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditionshttps://www.pharmaradar360.com/article/1-2026-4f0a4b02170c7516Pharma Surgeen2026-07-16T10:38:07.000ZΜΗΣΥΦΑ 1ου Τριμήνου 2026 _ Προτεινόμενες Τιμές προς Διαβούλευσηhttps://www.pharmaradar360.com/article/amylyx-nears-pivotal-endocrine-drug-study-readout-ff39615c409c8942Pharma Surgeen2026-07-16T10:35:33.000ZAmylyx nears pivotal endocrine drug study readouthttps://www.pharmaradar360.com/article/la-aemps-informa-de-la-retirada-del-mercado-de-determinadas-canulas-guedel-de-un-01a6419ed76e2626Pharma Surgeen2026-07-16T10:33:45.000ZLa AEMPS informa de la retirada del mercado de determinadas cánulas Guedel de una sola piezahttps://www.pharmaradar360.com/article/datroway-ec8ad2f1de7fa374Pharma Surgeen2026-07-16T10:33:28.000ZDatrowayhttps://www.pharmaradar360.com/article/biomarin-bmrn-wins-fda-review-for-voxzogo-full-approval-in-achondroplasia-40dbb7257304ea50Pharma Surgeen2026-07-16T10:31:37.000ZBioMarin (BMRN) Wins FDA Review For VOXZOGO Full Approval In Achondroplasiahttps://www.pharmaradar360.com/article/italy-s-angelini-pharma-completes-4-1-billion-state-backed-takeover-of-catalyst-01b453d29b162daePharma Surgeen2026-07-16T10:20:23.000ZItaly's Angelini Pharma completes $4.1 billion state-backed takeover of Catalysthttps://www.pharmaradar360.com/article/malaria-prevention-guidelines-for-travellers-from-the-uk-2026-bfdb8582fd85690ePharma Surgeen2026-07-16T10:08:15.000ZMalaria prevention guidelines for travellers from the UK 2026https://www.pharmaradar360.com/article/zymeworks-to-report-second-quarter-2026-financial-results-on-august-6-2026-68d6d4f3343f072cPharma Surgeen2026-07-16T10:04:10.000ZZymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026https://www.pharmaradar360.com/article/cordis-project-biocompatible-agents-for-preventive-diagnostics-in-vascular-disea-454831a2cc90b152Pharma Surgeen2026-07-16T10:00:35.000ZCORDIS project: Biocompatible agents for preventive diagnostics in vascular diseasehttps://www.pharmaradar360.com/article/cordis-project-engineering-microglia-to-treat-alzheimer-s-disease-b86b5f5df47034c1Pharma Surgeen2026-07-16T10:00:21.000ZCORDIS project: Engineering microglia to treat Alzheimer’s diseasehttps://www.pharmaradar360.com/article/cordis-project-in-vivo-targeting-of-neoepitopes-induced-by-arginine-deprivation-20c6a9ca97eaf459Pharma Surgeen2026-07-16T10:00:19.000ZCORDIS project: In vivo targeting of neoepitopes induced by arginine deprivation in cancerhttps://www.pharmaradar360.com/article/cordis-project-the-multi-heart-plate-a-human-engineered-mini-heart-platform-for-56593a192ed445e4Pharma Surgeen2026-07-16T10:00:12.000ZCORDIS project: The Multi-Heart Plate: a human engineered mini-heart platform for functional cardiac disease modelling and drug testinghttps://www.pharmaradar360.com/article/cordis-project-training-a-new-generation-to-decode-the-human-cis-regulatory-geno-c9b45ac5b44bc6e1Pharma Surgeen2026-07-16T10:00:12.000ZCORDIS project: Training a New Generation to Decode the Human Cis-Regulatory Genomehttps://www.pharmaradar360.com/article/cordis-project-drugging-the-undruggable-by-sampling-a-vast-chemical-space-of-mem-35efb27a7787b5ccPharma Surgeen2026-07-16T10:00:04.000ZCORDIS project: Drugging the “undruggable” by sampling a vast chemical space of membrane-permeable cyclic peptideshttps://www.pharmaradar360.com/article/cordis-project-preventing-drug-market-and-traffic-related-violence-through-innov-eb4df510e4e50a48Pharma Surgeen2026-07-16T10:00:03.000ZCORDIS project: Preventing drug market and traffic-Related violence through Innovative Solutions at the Municipal levelhttps://www.pharmaradar360.com/article/cordis-project-dorsal-root-ganglion-macrophages-as-novel-target-for-the-treatmen-c2db07fe7d6adff9Pharma Surgeen2026-07-16T10:00:02.000ZCORDIS project: Dorsal root ganglion macrophages as novel target for the treatment of chronic visceral painhttps://www.pharmaradar360.com/article/biomed-industries-presents-promising-phase-2-3-clinical-results-of-na-921-for-re-6af9732cd4b928fbPharma Surgeen2026-07-16T10:00:00.000ZBiomed Industries Presents Promising Phase 2/3 Clinical Results of NA-921 for Rett Syndrome at Orphan Drug Summit 2026https://www.pharmaradar360.com/article/harbour-biomed-and-kelun-biotech-receive-china-ind-approval-for-asthma-therapy-0b293e653e6af0a5Pharma Surgeen2026-07-16T09:59:04.000ZHarbour BioMed and Kelun-Biotech receive China IND approval for asthma therapyhttps://www.pharmaradar360.com/article/vogenx-c38a702ec62820c8Pharma Surgeen2026-07-16T09:58:43.000ZVogenxhttps://www.pharmaradar360.com/article/ebola-and-marburg-haemorrhagic-fevers-outbreaks-and-case-locations-16b29cdb0bb31831Pharma Surgeen2026-07-16T09:50:26.000ZEbola and Marburg haemorrhagic fevers: outbreaks and case locationshttps://www.pharmaradar360.com/article/j-j-tops-25-billion-quarter-lifts-2026-outlook-bece073262a14099Pharma Surgeen2026-07-16T09:47:32.000ZJ&J tops $25 billion quarter, lifts 2026 outlookhttps://www.pharmaradar360.com/article/outbreaks-under-monitoring-in-2026-eb6ae222898106b1Pharma Surgeen2026-07-16T09:44:51.000ZOutbreaks under monitoring in 2026https://www.pharmaradar360.com/article/la-aemps-informa-de-la-retirada-de-seis-lotes-del-medicamento-veterinario-moduli-bcd4952599605e76Pharma Surgeen2026-07-16T09:41:36.000ZLa AEMPS informa de la retirada de seis lotes del medicamento veterinario Modulis 100mg/ml solución oral para perroshttps://www.pharmaradar360.com/article/modulis-100-mg-ml-solucion-oral-para-perros-no-3178-esp-229f003566a30325Pharma Surgeen2026-07-16T09:40:34.000ZMODULIS 100 MG/ML SOLUCION ORAL PARA PERROS (Nº 3178 ESP)https://www.pharmaradar360.com/article/bayer-adds-a-spine-to-modularity-for-scale-without-disruption-7d6fd16e3046de5fPharma Surgeen2026-07-16T09:24:30.000ZBayer Adds A Spine To Modularity For Scale Without Disruptionhttps://www.pharmaradar360.com/article/nihr-sphr-transdisciplinary-fellowships-in-public-health-research-2026-1f2621f6ecd2812aPharma Surgeen2026-07-16T09:23:29.000ZNIHR SPHR Transdisciplinary Fellowships in public health research 2026https://www.pharmaradar360.com/article/krystal-biotech-nasdaq-krys-shows-high-growth-momentum-with-perfect-minervini-tr-3623183038eb9a0bPharma Surgeen2026-07-16T09:20:28.000ZKrystal Biotech (NASDAQ:KRYS) Shows High-Growth Momentum With Perfect Minervini Trend Template Setuphttps://www.pharmaradar360.com/article/vogenx-joins-the-ipo-queue-to-fund-phase-2-stage-metabolic-drug-3ea5708412500b7dPharma Surgeen2026-07-16T09:19:05.000ZVogenx joins the IPO queue to fund phase 2-stage metabolic drughttps://www.pharmaradar360.com/article/global-penny-stocks-guizhou-yibai-pharmaceutical-and-2-more-to-watch-a1ee61041a90e090Pharma Surgeen2026-07-16T09:15:54.000ZGlobal Penny Stocks: Guizhou Yibai Pharmaceutical And 2 More To Watchhttps://www.pharmaradar360.com/article/top-five-global-pharma-signs-deal-to-test-kangstem-s-hair-follicle-organoids-for-5ffaa0e135f070f4Pharma Surgeen2026-07-16T09:03:49.000ZTop-five global pharma signs deal to test Kangstem’s hair follicle organoids for hair-loss drugshttps://www.pharmaradar360.com/article/harbour-biomed-and-kelun-biotech-receive-china-ind-approval-for-asthma-therapy-53613018630f4883Pharma Surgeen2026-07-16T09:00:28.000ZHarbour BioMed and Kelun-Biotech receive China IND approval for asthma therapyhttps://www.pharmaradar360.com/article/on-behalf-of-respighi-bidco-s-p-a-press-release-pursuant-to-article-36-of-the-is-0643304fbc750a67Pharma Surgeen2026-07-16T08:54:00.000ZOn behalf of Respighi BidCo S.p.A – Press Release pursuant to Article 36 of the Issuers’ Regulation